ATXS

Astria Therapeutics Inc

Sep 18 • 11:55AM ET

7.43

+0.04 0.51 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX PFE GILD AMGN BIIB SRPT ALNY NBIX BLUE

| Held by: VTI IWM IWN VXF IBB VTWO SCHA IWC DFAC VHT

Index	RUT	P/E	-	EPS (ttm)	-2.03	Insider Own	19.75%	Shs Outstand	56.43M	Perf Week	-5.26%
Market Cap	419.19M	Forward P/E	-	EPS next Y	-2.24	Insider Trans	0.00%	Shs Float	45.29M	Perf Month	17.90%
Enterprise Value	260.10M	PEG	-	EPS next Q	-0.42	Inst Own	82.82%	Short Float	6.15%	Perf Quarter	26.11%
Income	-116.92M	P/S	-	EPS this Y	-24.28%	Inst Trans	-2.11%	Short Ratio	9.23	Perf Half Y	17.72%
Sales	0.00M	P/B	2.54	EPS next Y	-7.10%	ROA	-35.98%	Short Interest	2.79M	Perf YTD	-16.91%
Book/sh	2.93	P/C	1.62	EPS next 5Y	-8.47%	ROE	-38.49%	52W High	12.92 -42.51%	Perf Year	-33.86%
Cash/sh	4.59	P/FCF	-	EPS past 3/5Y	59.12% 34.65%	ROIC	-44.31%	52W Low	3.56 108.95%	Perf 3Y	-26.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.35% 7.00%	Perf 5Y	-80.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	11.81%	Oper. Margin	-	ATR (14)	0.48	Perf 10Y	-98.88%
Dividend Ex-Date	-	Quick Ratio	14.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.89	EPS Q/Q	-33.16%	SMA20	5.57%	Beta	0.41	Target Price	29.78
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	9.77%	Rel Volume	1.34	Prev Close	7.39
Employees	78	LT Debt/Eq	0.01	Earnings	Aug 12 AMC	SMA200	13.47%	Avg Volume	302.00K	Price	7.43
IPO	Jun 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.13% -	Trades		Volume	163,181	Change	0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Reiterated	H.C. Wainwright	Buy	$16 → $20
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$47
Jan-31-25	Initiated	JMP Securities	Mkt Outperform	$26
Jul-29-24	Initiated	TD Cowen	Buy	$35
Mar-28-23	Initiated	Evercore ISI	Outperform	$18

Sep-17-25 08:00AM	Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology (Business Wire)
Sep-11-25 12:00PM	All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade (Zacks)
Sep-08-25 05:03PM	Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Sep-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.07%
08:00AM	Loading…
08:00AM	Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025 (Business Wire)
Sep-02-25 07:30AM	2 Strong Buy Growth Stocks Offering 300% or Higher Upside (Barchart) +6.63%
Aug-27-25 08:00AM	Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference (Business Wire)
Aug-15-25 09:55AM	Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 04:10PM	Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire)
Aug-07-25 05:55AM	Astria Therapeutics licenses navenibart rights to Kaken for HAE (Pharmaceutical Technology)
Aug-06-25 08:00AM	Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan (Business Wire)
Aug-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.03%
Jul-31-25 11:40PM	Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients (Insider Monkey) -5.20%
Jul-07-25 08:00AM	Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit (Business Wire) +6.71%
04:10PM	Loading…
Jul-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.52%
Jun-18-25 08:00AM	Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit (Business Wire)
Jun-13-25 07:00AM	Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress (Business Wire)
Jun-06-25 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress (Business Wire) +14.75%
Jun-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.45%
May-28-25 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference (Business Wire) +6.85%
May-23-25 08:00AM	Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop (Business Wire)
May-22-25 08:00AM	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference (Business Wire)
May-13-25 04:10PM	Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire) -10.76%
May-09-25 08:30AM	Is Astria Therapeutics, Inc. (ATXS) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-25 08:00AM	Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology (Business Wire)
Apr-30-25 08:00AM	Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.70%
Mar-11-25 08:00AM	Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update (Business Wire) +11.17%
04:10PM	Loading…
Mar-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 08:00AM	Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema (Business Wire)
Feb-25-25 08:00AM	Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-20-25 08:00AM	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress (Business Wire)
Feb-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-03-25 08:00AM	Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session (Business Wire) -5.47%
Jan-23-25 08:00AM	Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis (Business Wire)
Jan-13-25 08:00AM	Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE (Business Wire)
Jan-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 08:00AM	Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE (Business Wire)
Dec-10-24 08:00AM	Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis (Business Wire)
Dec-03-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 04:10PM	Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference (Business Wire)
Nov-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting (Business Wire)
Oct-21-24 08:00AM	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Oct-17-24 08:16AM	Astria Therapeutics' navenibart gains orphan medicinal status from EC (Pharmaceutical Business Review)
Oct-16-24 08:00AM	European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics Investigational Therapy for the Treatment of Hereditary Angioedema (Business Wire)
Oct-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 08:00AM	Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema (Business Wire)
Sep-27-24 08:00AM	Astria Therapeutics to Present at Upcoming Global Angioedema Forum (Business Wire)
Sep-19-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress (Business Wire) +6.37%
Sep-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Bradykinin Symposium (Business Wire)
Aug-29-24 08:00AM	Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-12-24 04:10PM	Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +7.48%
04:00PM	Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema (Business Wire)
Aug-07-24 08:00AM	Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference (Business Wire)
Aug-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.61% -5.36%
Jul-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference (Business Wire)
May-24-24 08:00AM	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference (Business Wire)
May-23-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress (Business Wire)
May-09-24 04:10PM	Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +6.27%
May-08-24 08:00AM	Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting (Business Wire)
May-02-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-09-24 08:00AM	Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors (Business Wire)
Apr-03-24 07:00PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS) (GuruFocus.com) -5.47%
04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-25-24 07:30AM	Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE (Business Wire)
Mar-05-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.14%
Mar-04-24 10:52PM	ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-20-24 08:00AM	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-06-24 08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +6.25%
Feb-05-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.95%
Jan-30-24 07:29PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (GuruFocus.com) +6.62%
09:08AM	Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering (Business Wire)
Dec-04-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-23 08:00AM	Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress (Business Wire)
Nov-21-23 08:00AM	Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-14-23 01:07PM	Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 11:07AM	Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments (GuruFocus.com)
08:00AM	Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update (Business Wire)
Nov-10-23 08:00AM	Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Nov-09-23 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference (Business Wire)
Nov-03-23 08:10AM	Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting (Business Wire)
Nov-02-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-30-23 08:00AM	Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th (Business Wire)
Oct-11-23 07:14PM	Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering (Business Wire)
05:10PM	Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio (Business Wire)
Oct-03-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-23 08:00AM	Astria Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-31-23 08:00AM	Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics (Business Wire)
Aug-30-23 10:01AM	2 Strong Buy Stocks Under $10 That Oppenheimer Sees Surging Over 200% Heres Why They Could Jump (TipRanks)
Aug-25-23 08:00AM	Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference (Business Wire)

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATXS

Astria Therapeutics Inc

Upgrade your FINVIZ experience